64th ACNP Annual Meeting Nassau, Bahamas | Jan 2026

Autobahn Therapeutics Presents New Preclinical Data Supporting Novel Neuroplasticity Mechanism of Elunetirom

SAN DIEGO — Autobahn Therapeutics, a biotechnology company developing restorative treatments for neuropsychiatric disorders, has unveiled new data for elunetirom. This lead asset, a CNS-selective TRβ agonist, is being positioned as a potential breakthrough for adjunctive major depressive disorder (MDD) and bipolar depression.

Restorative Neuroplasticity

Unlike traditional therapies, elunetirom targets thyroid-beta hormone receptors (CNS-TRs) in the brain. This mechanism is designed to drive the persistent strengthening of neuronal synapses and modulate plasticity, addressing the underlying neural dysfunction often left untouched by existing treatments.

"Selective and potent activation of CNS-TRs represents a different approach to treating depression. This new mechanism may address underlying neural dysfunction in patients who have not benefited from existing therapies."

— Jonathan Meyer, MD, University of California, San Diego

Key Preclinical Evidence

Cortical Neuron Culture

• Significant increase in the total number of neurons.
• Enhanced neurite length and root formation.
• Increased number of neurite extremities, facilitating network density.

Hippocampal Analysis

• Elevated markers of neuritogenesis.
• Promotion of synaptogenesis (formation of new synapses).
• Performance comparable to optimal concentrations of BDNF.

The data further characterize elunetirom’s impact on BDNF (Brain-Derived Neurotrophic Factor), a major driver of synaptic formation. This provides strong mechanistic support for its role in energy-dependent neuroplasticity.

2026 Clinical Roadmap

Q2 2026 AMPLIFY-BD Topline Data
(Bipolar Depression)

Q3 2026 AMPLIFY Topline Data
(Major Depressive Disorder)

Elunetirom is currently in Phase 2 clinical development. These findings increase confidence in the ongoing AMPLIFY program, offering hope for millions of patients who do not achieve adequate relief with current pharmacological approaches.